Cangrelor: A review on pharmacology and clinical trial development

Expert Review of Cardiovascular Therapy

Volumn 11, Issue 10, 2013, Pages 1279-1291

  Franchi, Francesco ^a   Rollini, Fabiana ^a   Muñiz Lozano, Ana ^a   Rae Cho, Jung ^a   Angiolillo, Dominick J ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Acute coronary syndrome; Antiplatelet therapy; Cangrelor; P2Y12 receptor antagonist; Percutaneous coronary intervention

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ALTEPLASE; CANGRELOR; CLOPIDOGREL; PLACEBO; PRASUGREL; PURINERGIC P2Y RECEPTOR; PURINERGIC P2Y RECEPTOR ANTAGONIST; TICAGRELOR; TICLOPIDINE;

ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CARDIOVASCULAR SYMPTOM; CLINICAL TRIAL (TOPIC); CONTINUOUS INFUSION; DIABETES MELLITUS; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DYSPNEA; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART SURGERY; HUMAN; LOADING DRUG DOSE; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME;

ACUTE CORONARY SYNDROME; ADENOSINE MONOPHOSPHATE; ANIMALS; ASPIRIN; CLINICAL TRIALS AS TOPIC; DRUG THERAPY, COMBINATION; HUMANS; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; PURINERGIC P2Y RECEPTOR ANTAGONISTS;

EID: 84886632179     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.2013.837701     Document Type: Article

References (56)

1. Storey RF, Newby LJ, Heptinstall S. Effects of P2Y1 and P2Y12 receptor antagonists on platelet aggregation induced by different agonists in human whole blood. Platelets 12 (7), 443-447 (2001).
2. Gachet C. ADP receptors of platelets and their inhibition. Thromb. Haemost. 86 (1), 222-232 (2001).
3. Angiolillo DJ, Ueno M, Goto S. Basic principles of platelet biology and clinical implications. Circ. J. 74 (4), 597-607 (2010).
4. Yusuf S, Zhao F, Mehta SR et al. The clopidogrel in unstable angina to prevent recurrent events trial investigators. effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N. Engl. J. Med. 345 (7), 494-502 (2001).
5. Steinhubl SR, Berger PB, Mann JT 3rd et al. CREDO Investigators. Clopidogrel for the reduction of events during observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: A randomized controlled trial. JAMA 288 (19), 2411-2420 (2002).
6. Chen ZM, Jiang LX, Chen YP et al. COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: Randomised placebo-controlled trial. Lancet 366 (9497), 1607-1621 (2005).
7. Wiviott SD, Braunwald E, McCabe CH et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med 357 (20), 2001-2015 (2007).
8. Wallentin L, Becker RC, Budaj A et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 361 (11), 1045-1057 (2009)
9. Steg PG, James SK, Atar D et al. The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur. Heart J. 33 (20), 2569-2619 (2012).
10. Hamm CW, Bassand JP, Agewall S et al. ESC Committee for Practice Guidelines. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur. Heart J. 32 (23), 2999-3054 (2011).
11. American College of Emergency Physicians; Society for Cardiovascular Angiography and Interventions; O'Gara PT, Kushner FG, Ascheim DD et al. 2013 ACCF/ AHA guideline for the management of ST-elevation myocardial infarction: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol. 61 (4), e78-e140 (2013).
12. Jneid H, Anderson JL, Wright RS et al. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST- elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol. 60 (7), 645-681 (2012).
13. Levine GN, Bates ER, Blankenship JC et al. ACCF/AHA/SCAI guideline for percutaneous coronary intervention: A report of the american college of cardiology foundation/american heart association task force on practice guidelines and the society for cardiovascular angiography and interventions. J. Am. Coll. Cardiol. 58 (24), e44-e122 (2011).
14. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E et al. Variability in individual responsiveness to clopidogrel: Clinical implications, management, and future perspectives. J. Am. Coll. Cardiol. 49 (14), 1505-1516 (2007).
15. Ferreiro JL, Angiolillo DJ. Clopidogrel response variability: Current status and future directions. Thromb. Haemost. 102 (1), 7-14 (2009).
16. Angiolillo DJ, Ferreiro JL. Platelet adenosine diphosphate P2Y12 receptor antagonism: Benefits and limitations of current treatment strategies and future directions. Rev. Esp. Cardiol. 63 (1), 60-76 (2010).
17. Bonello L, Tantry US, Marcucci R et al. Consensus and future directions on the definition of high on-Treatment platelet reactivity to adenosine diphosphate. J. Am. Coll. Cardiol. 56 (12), 919-33 (2010).
18. Ferreiro JL, Angiolillo DJ. New directions in antiplatelet therapy. Circ. Cardiovasc. Interv. 5 (3), 433-45 (2012).
19. Alexopoulos D, Xanthopoulou I, Gkizas V et al. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction. Circ. Cardiovasc. Interv. 5 (6), 797-804 (2012).
20. Parodi G, Valenti R, Bellandi B et al. Comparison of prasugrel and ticagrelor loading doses in st-segment elevation myocardial infarction patients: Rapid (rapid activity of platelet inhibitor drugs) primary pci study. J. Am. Coll. Cardiol. 61 (15), 1601-1606 (2013).
21. Gurbel PA, Bliden KP, Butler K et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: The ONSET/OFFSET study. Circulation 120 (25), 2577-2585 (2009).
22. Price MJ, Walder JS, Baker BA et al. Recovery of platelet function after discontinuation of prasugrel or clopidogrel maintenance dosing in aspirin-Treated patients with stable coronary disease: The recovery trial. J. Am. Coll. Cardiol. 59 (25), 2338-2343 (2012).
23. Osmancik P, Jirmar R, Hulikova K et al. A comparison of the VASP index between patients with hemodynamically complicated and uncomplicated acute myocardial infarction. Catheter Cardiovasc. Interv. 75 (2), 158-166 (2010).
24. Heestermans AA, van Werkum JW, Taubert D et al. Impaired bioavailability of clopidogrel in patients with a ST-segment elevation myocardial infarction. Thromb. Res. 122 (6), 776-781 (2008).
25. Ueno M, Ferreiro JL, Angiolillo DJ. Update on the clinical development of cangrelor. Expert Rev. Cardiovasc. Ther. 8 (8), 1069-1077 (2010).
26. Ferreiro JL, Ueno M, Angiolillo DJ. Cangrelor: A review on its mechanism of action and clinical development. Expert Rev. Cardiovasc Ther. 7 (10), 1195-201 (2009).
27. Dorsam RT, Kunapuli SP. Central role of the P2Y12 receptor in platelet activation. J. Clin. Invest. 113 (3), 340-345 (2004).
28. Hechler B, Vigne P, Léon C, Breittmayer JP, Gachet C, Frelin C. ATP derivatives are antagonists of the P2Y1 receptor: Similarities to the platelet ADP receptor. Mol. Pharmacol. 53 (4), 727-733 (1998).
29. Ingall AH, Dixon J, Bailey A et al. Antagonists of the platelet P2T receptor: A novel approach to antithrombotic therapy. J. Med. Chem. 42 (2), 213-220 (1999).
30. van Giezen JJ, Humphries RG. Preclinical and clinical studies with selective reversible direct P2Y12 antagonists. Semin. Thromb. Hemost. 31 (2), 195-204 (2005).
31. Nassim MA, Sanderson JB, Clarke C et al. Investigation of the novel P2T receptor antagonist AR-C69931MX on ex vivo adenosine diphosphate-induced platelet aggregation and bleeding time in healthy volunteers. J. Am. Coll. Cardiol. 33 (2 Suppl. A), A255 (1999).
32. Javis GE, Nassim MA, Humphries RG et al. The P2Y antagonist AR-C69931MX is a more effective inhibitor of ADP-induced platelet aggregation than clopidogrel. Blood 94 (Suppl. 1), A22 (1999).
33. Aleil B, Ravanat C, Cazenave JP, Rochoux G, Heitz A, Gachet C. Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases. J. Thromb. Haemost. 3 (1), 85-92 (2005).
34. Storey RF, Oldroyd KG, Wilcox RGOpen multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndrome. Thromb. Haemost. 85 (3), 401-407 (2001).
35. Greenbaum AB, Ohman EM, Gibson CM et al. Preliminary experience with intravenous P2Y12 platelet receptor inhibition as an adjunct to reduced-dose alteplase during acute myocardial infarction: Results of the Safety, Tolerability and Effect on Patency in Acute Myocardial Infarction (STEP-AMI) angiographic trial. Am. Heart J. 154 (4), 702-709 (2007).
36. Greenbaum AB, Grines CL, Bittl JA et al. Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: Results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial. Am. Heart J. 151 (3), 689.e1-689.e10 (2006).
37. Ferreiro JL, Angiolillo DJ. Diabetes and antiplatelet therapy in acute coronary syndrome. Circulation 123 (7), 798-813 (2011).
38. Ferreiro JL, Ueno M, Tello-Montoliu A et al. Effects of cangrelor in coronary artery disease patients with and without diabetes mellitus: An in vitro pharmacodynamic investigation. J. Thromb. Thrombolysis 35 (2), 155-164 (2013).
39. Steinhubl SR, Oh JJ, Oestreich JH, Ferraris S, Charnigo R, Akers WS. Transitioning patients from cangrelor to clopidogrel: Pharmacodynamic evidence of a competitive effect. Thromb. Res. 121 (4), 527-534 (2008).
40. Dovlatova NL, Jakubowski JA, Sugidachi A, Heptinstall S. The reversible P2Y antagonist cangrelor influences the ability of the active metabolites of clopidogrel and prasugrel to produce irreversible inhibition of platelet function. J. Thromb. Haemost. 6 (7), 1153-1159 (2008).
41. Ravnefjord A, Weilitz J, Emanuelsson BM, van Giezen JJ. Evaluation of ticagrelor pharmacodynamic interactions with reversibly binding or non-reversibly binding P2Y12 antagonists in an ex-vivo canine model. Thromb. Res. 130 (4), 622-628 (2012).
42. Brilakis ES, Banerjee S, Berger PB. Perioperative management of patients with coronary stents. J. Am. Coll. Cardiol. 49 (22), 2145-2150 (2007).
43. Savonitto S, Caracciolo M, Cattaneo M, DE Servi S. Management of patients with recently implanted coronary stents on dual antiplatelet therapy who need to undergo major surgery. J. Thromb. Haemost. 9 (11), 2133-2142 (2011).
44. Rossini R, Bramucci E, Castiglioni B et al. Coronary stenting and surgery: Perioperative management of antiplatelet therapy in patients undergoing surgery after coronary stent implantation. G. Ital. Cardiol. (Rome). (7-8), 528-551 (2012).
45. Bhatt DL, Topol EJ. Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. JAMA 284 (12), 1549-1558 (2000).
46. Angiolillo DJ, Firstenberg MS, Price MJ et al.; BRIDGE Investigators. Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: A randomized controlled trial. JAMA 307 (3), 265-274 (2012).
47. Welsh RC, Rao SV, Zeymer U et al. INNOVATE-PCI Investigators. A randomized, double-blind, active-controlled phase 2 trial to evaluate a novel selective and reversible intravenous and oral P2Y12 inhibitor elinogrel versus clopidogrel in patients undergoing nonurgent percutaneous coronary intervention: The INNOVATE-PCI trial. Circ. Cardiovasc. Interv. 5 (3), 336-346 (2012).
48. Ueno M, Rao SV, Angiolillo DJ. Elinogrel: Pharmacological principles, preclinical and early phase clinical testing. Future Cardiol. 6 (4), 445-453 (2010).
49. Harrington RA, Stone GW, McNulty S et al. Platelet Inhibition with Cangrelor in Patients Undergoing PCI. N. Engl. J. Med. 361 (24), 2318-2329 (2009).
50. Bhatt DL, Lincoff M, Gibson M et al. Intravenous Platelet Blockade with Cangrelor during PCI. N. Engl. J. Med. 361 (24), 2330-2341 (2009).
51. Angiolillo DJ, Schneider DJ, Bhatt DL et al. Pharmacodynamic effects of cangrelor and clopidogrel: The platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION) trials. J. Thromb. Thrombolysis 34 (1), 44-55 (2012).
52. White HD, Chew DP, Dauerman HL et al. Reduced immediate ischemic events with cangrelor in PCI: A pooled analysis of the CHAMPION trials using the universal definition of myocardial infarction. Am. Heart J. 163 (2), 182-90.e4 (2012).
53. Thygesen K, Alpert JS, White HD et al. Universal definition of myocardial infarction. Circulation 116 (22), 2634-2653 (2007).
54. Leonardi S, Mahaffey KW, White HD et al. Rationale and design of the Cangrelor versus standard therapy to achieve optimal Management of Platelet InhibitiON PHOENIX trial. Am. Heart J. 163 (5), 768-776.e2 (2012).
55. Bhatt DL, Stone GW, Mahaffey KW et al. CHAMPION PHOENIX Investigators. Effect of platelet inhibition with cangrelor during PCI on ischemic events. N. Engl. J. Med. 368 (14), 1303-1313 (2013).
56. Widimsky P, Motovská Z, Simek S et al. Clopidogrel pre-Treatment in stable angina: For all patients > 6 h before elective coronary angiography or only for angiographically selected patients a few minutes before PCI? A randomized multicentre trial PRAGUE-8. Eur. Heart J. 29 (12), 1495-1503 (2008).